Literature DB >> 33594259

Machine learning approaches to drug response prediction: challenges and recent progress.

George Adam1,2,3, Ladislav Rampášek2,3,4, Zhaleh Safikhani1,3,5, Petr Smirnov1,3,6, Benjamin Haibe-Kains7,8,9,10,11, Anna Goldenberg12,13,14.   

Abstract

Cancer is a leading cause of death worldwide. Identifying the best treatment using computational models to personalize drug response prediction holds great promise to improve patient's chances of successful recovery. Unfortunately, the computational task of predicting drug response is very challenging, partially due to the limitations of the available data and partially due to algorithmic shortcomings. The recent advances in deep learning may open a new chapter in the search for computational drug response prediction models and ultimately result in more accurate tools for therapy response. This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts. The incorporation of new data modalities such as single-cell profiling, along with techniques that rapidly find effective drug combinations will likely be instrumental in improving cancer care.

Year:  2020        PMID: 33594259     DOI: 10.1038/s41698-020-0122-1

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN: 2397-768X


  93 in total

1.  Precision oncology: an overview.

Authors:  Levi A Garraway; Jaap Verweij; Karla V Ballman
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

2.  Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.

Authors:  Michael Q Ding; Lujia Chen; Gregory F Cooper; Jonathan D Young; Xinghua Lu
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

3.  Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.

Authors:  M Doherty; T Metcalfe; E Guardino; E Peters; L Ramage
Journal:  Ann Oncol       Date:  2016-04-26       Impact factor: 32.976

4.  Current advances in public health dentistry.

Authors:  C W McPhail
Journal:  Can J Public Health       Date:  1965-12

5.  The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Authors:  Amber Johnson; Jia Zeng; Ann M Bailey; Vijaykumar Holla; Beate Litzenburger; Humberto Lara-Guerra; Gordon B Mills; John Mendelsohn; Kenna R Shaw; Funda Meric-Bernstam
Journal:  Drug Discov Today       Date:  2015-07-03       Impact factor: 7.851

Review 6.  Drug-biomarker co-development in oncology - 20 years and counting.

Authors:  Julianne D Twomey; Nina N Brahme; Baolin Zhang
Journal:  Drug Resist Updat       Date:  2017-02-21       Impact factor: 18.500

7.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

Review 8.  KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

Authors:  Wendy De Roock; Veerle De Vriendt; Nicola Normanno; Fortunato Ciardiello; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-12-14       Impact factor: 41.316

9.  Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Authors:  John Heymach; Lada Krilov; Anthony Alberg; Nancy Baxter; Susan Marina Chang; Ryan B Corcoran; William Dale; Angela DeMichele; Catherine S Magid Diefenbach; Robert Dreicer; Andrew S Epstein; Maura L Gillison; David L Graham; Joshua Jones; Andrew H Ko; Ana Maria Lopez; Robert G Maki; Carlos Rodriguez-Galindo; Richard L Schilsky; Mario Sznol; Shannon Neville Westin; Harold Burstein
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

10.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Authors:  Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.